Monday, 9 September 2013

PubMed Update August 2013


16 papers today – this is getting to be a big job. Naloxone, fentanyl, methadone, stars, pain, Central Asia, primary care, injection facilities, personal stories …

Centers for Disease Control and Prevention (CDC).
MMWR Morb Mortal Wkly Rep. 2013 Aug 30;62(34):703-4.
Comment: The evidence of synthetic fentanyl was difficult to detect and concerning to many as heralding a possible repeat of the 2006/2007 fentanyl-tainted heroin overdose outbreak.

Saifan C, Glass D, Barakat I, El-Sayegh S.
Case Rep Med. 2013;2013:242730. doi: 10.1155/2013/242730. Epub 2013 Jul 29.
Comment: In this case the patient was restarted on methadone and the sensorineural hearing loss was permanent.

Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC.
Cochrane Database Syst Rev. 2013 Aug 27;8:CD004959. doi:
Comment: There are no quality data to support long-term management of non-cancer pain with opioids.

Willens JS.
Pain Manag Nurs. 2013 Sep;14(3):125. doi: 10.1016/j.pmn.2013.07.004. No abstract available.
Comment: The Glee star.


Shadnia S, Rahimi M, Hassanian-Moghaddam H, Soltaninejad K, Noroozi A.
Clin Toxicol (Phila). 2013 Aug 23. [Epub ahead of print]
Comment: Accidental poisonings among family in Iran for (insufficiently-labeled) take-home methadone syrup.

Teo A, Cooper J.
Scott Med J. 2013 Aug;58(3):149-53. doi: 10.1177/0036933013496951.
Comment: I’m unable to access this paper. It’s a review of overdose events at a Scottish hospital; 4% were administered naloxone.

Gilbert L, Primbetova S, Nikitin D, Hunt T, Terlikbayeva A, Momenghalibaf A, Ruziev M, El-Bassel N.
Drug Alcohol Depend. 2013 Aug 13. doi:pii: S0376-8716(13)00282-2.
Comment: A really interesting approach to thinking about HIV and drug overdose mortality, through the lens of syndemics – a hot topic in public health – and risk environments. With the bonus of an important review of data from several Central Asian states.

Bernstein HG, Trübner K, Krebs P, Dobrowolny H, Bielau H, Steiner J, Bogerts B.
Acta Histochem. 2013 Aug 13. doi:pii: S0065-1281(13)00145-1.
Comment: Interesting analysis comparing heroin overdose patients to controls, although I’m unclear it’s direct relationship to the pathologic processes of overdose.

Heimer R, Barbour R, Palacios WR, Nichols LG, Grau LE.
AIDS Behav. 2013 Aug 7. [Epub ahead of print]
Comment: Intriguing paper on rural heroin use.

Chahua M, Sordo L, Barrio G, Domingo-Salvany A, Brugal MT, Molist G, de la Fuente L, Bravo MJ.
Eur Addict Res. 2013 Aug 1;20(1):1-7. [Epub ahead of print]
Comment: There haven’t been many overdose studies out of Spain. Nice to see this.

Bowman S, Eiserman J, Beletsky L, Stancliff S, Bruce RD.
Am J Med. 2013 Jul;126(7):565-71. doi: 10.1016/j.amjmed.2012.11.031. Epub 2013 May 8. Review.
Comment: Kudos to the authors for getting out to primary care providers information on simple harm reduction practices that can be employed in clinical settings.

Taylor R Jr, Pergolizzi JV Jr, Porreca F, Raffa RB.
Expert Opin Investig Drugs. 2013 Apr;22(4):517-25. doi: 10.1517/13543784.2013.778973. Review.
Comment: Fascinating paper on the analgesic properties of opioid ANTagonists.

Jozaghi E, Andresen MM.
Harm Reduct J. 2013 Feb 16;10:1. doi: 10.1186/1477-7517-10-1.
Comment: A discussion including the benefits of supervised injection facilities in reducing overdose deaths, sharing of injection equipment, public drug use, and utilization of emergency medical services.

Algren DA, Monteilh CP, Punja M, Schier JG, Belson M, Hepler BR, Schmidt CJ, Miller CE, Patel M, Paulozzi LJ, Straetemans M, Rubin C.
J Med Toxicol. 2013 Mar;9(1):106-15. doi: 10.1007/s13181-012-0285-4.
Comment: A review of pathological details related to the tragic 2005-2007 fentanyl-tainted heroin outbreak.

George S, Boulay S, Begley D.
BMJ Case Rep. 2010 Sep 7;2010. doi:pii: bcr0520102986.
Comment: A rare example in the medical literature, this paper includes several paragraphs of direct patient perspective on administering naloxone. Read the free full-text from BMJ.

Reece AS.
BMJ Case Rep. 2010 Sep 7;2010. doi:pii: bcr0420102871. 10.1136/bcr.04.2010.2871. Review.
Comment: The hepatotoxicity concerns with naltrexone were based on doses of around 2 grams, which would be considered massive today.

Sunday, 4 August 2013

PubMed Update July 2013


8 papers this month. Police, pharmacology, prisons, methadone, money, and plants. Enjoy!

Banta-Green CJ, Beletsky L, Schoeppe JA, Coffin PO, Kuszler PC.
J Urban Health. 2013 Jul 31. [Epub ahead of print]
Comment: Expands on the limited data we have regarding police and paramedics knowledge and opinions regarding opioid overdose prevention initiatives.

Demaret I, Lemaître A, Ansseau M.
Rev Med Liege. 2013 May-Jun;68(5-6):287-93. French.
Comment: Only saw the abstract, but appears to be a nice summary of heroin, particularly overdose risk factors.

Fudin J, Fontenelle DV, Fudin HR, Carlyn C, Hinden DA, Ashley CC.
J Pain Palliat Care Pharmacother. 2013 Jul 24. [Epub ahead of print]
Comment: Some potential interactions of the HCV protease inhibitor with selected opioids. Hopefully we won’t be using telaprevir too much longer as more advanced, effective, and easily tolerated regimens are expected as early as the end of 2013.

Moore E, Winter R, Indig D, Greenberg D, Kinner SA.
Drug Alcohol Depend. 2013 Jul 15. doi:pii: S0376-8716(13)00220-2.
Comments: Survey of prisoners lifetime history of overdose.

Hall MT, Leukefeld CG, Havens JR.
Am J Drug Alcohol Abuse. 2013 Jul;39(4):241-6. doi:
Comment: I can’t access this article, but have some concerns about the utility of the analysis of covariates presented in the abstract.

Wunsch MJ, Nuzzo PA, Behonick G, Massello W, Walsh SL.
J Addict Med. 2013 Jul 8. [Epub ahead of print]
Comments: Analysis of methadone-related deaths.

Inocencio TJ, Carroll NV, Read EJ, Holdford DA.
Pain Med. 2013 Jul 10. doi: 10.1111/pme.12183. [Epub ahead of print]
Comments: Intriguing analysis of costs of opioid overdose, focusing on the costs to the healthcare system.

Neerman MF, Frost RE, Deking J.
J Forensic Sci. 2013 Jan;58 Suppl 1:S278-9. doi: 10.1111/1556-4029.12009. Epub 2012 Oct 19.
Comments: Kratom is a plant that grows in North America (this case is from Texas) and many other parts of the world. Its use is prohibited in Thailand. It acts as a mu-opioid receptor agonist.

Friday, 12 July 2013

Naloxone laws to reduce overdose - update

Back by popular demand is the map of U.S. states with legislation improving lay naloxone access. This post was delayed by a very active legislative season which I think has slowed down for the moment. As usual, this may have errors so please comment and I'll correct. 

This time I've only included states on the map (in black) with existing legislation improving lay naloxone access (e.g. not Oklahoma and Ohio as those bills target first responder access to naloxone, and not pending legislation that improves access in states - like California - that already have it). There are now lay naloxone access laws in CA, CO, CT, IL, KY, MA, MD, NJ, NC, NM, NY, OR, RI, VA, VT, WA, and the District of Columbia.


Unsuccessful bills this season included Maine and West Virginia.


Here's a summary from the Network for Public Health Law of naloxone (and Good Samaritan) laws that is kept regularly updated.












Tuesday, 9 July 2013

PubMed Update June 2013


13 new papers this month, from drug development to naloxone programming, epidemiology to practice management, toxicology to supply side drug control.

Li W, Gunja N.
Aust Fam Physician. 2013 Jul;42(7):481-5.
Comment: Unable to access.  Appears to be a general review of managing illicit drug toxicities.

Leece PN, Hopkins S, Marshall C, Orkin A, Gassanov MA, Shahin RM.
Can J Public Health. 2013 Apr 18;104(3):e200-4.
Comment: Unable to access. There have been several papers describing the initial experience of naloxone programs and this is a welcome addition to that literature.

Centers for Disease Control and Prevention (CDC).
MMWR Morb Mortal Wkly Rep. 2013 Jul 5;62(26):537-42.
Comment: A review of drug overdose mortality data among women, demonstrating that women have been particularly affected by the recent epidemic.

Coffin PO, Sullivan SD.
J Med Econ. 2013 Jun 19. [Epub ahead of print]
Comments: An adaptation of the model developed for the United States, taking into account structural differences, epidemiologic data, and costs in Russia. Because of limitations in emergency medical services in Russia, the high rate at which overdoses are witnessed, and the very low costs of naloxone, this intervention is likely to be even more cost-effective in Russia than it appears to be in the United States.


Ahmad SA, Scolnik D, Snehal V, Glatstein M.
Am J Ther. 2013 Jun 18. [Epub ahead of print]
Comment: I was curious as to why one would use naloxone in this circumstance – and no surprise it did not work.

Jones JD, Roux P, Stancliff S, Matthews W, Comer SD.
Int J Drug Policy. 2013 Jun 14. doi:pii: S0955-3959(13)00080-7.
Comment: Brief training on overdose prevention works.

Sherman SG, Han J, Welsh C, Chaulk P, Serio-Chapman C.
Am J Public Health. 2013 Jun 13. [Epub ahead of print]
Schwartz RP, Gryczynski J, O'Grady KE, Sharfstein JM, Warren G, Olsen YK, Mitchell SG, Jaffe JH.
Am J Public Health. 2013 Jun 13. [Epub ahead of print]
Comment: An intriguing dialogue about the Baltimore paper on opioid agonist treatment and overdose. That’s all I’ll say.

Corré J, Pillot J, Hilbert G.
Case Rep Radiol. 2013;2013:602981. doi: 10.1155/2013/602981. Epub 2013 May 22.
Comment: Cerebellar and basal ganglia damage from methadone overdose.

Zaller ND, Yokell MA, Green TC, Gaggin J, Case P.
Subst Use Misuse. 2013 Jun;48(8):590-9. doi: 10.3109/10826084.2013.793355. Epub 2013 Jun 10.
Comment: Unable to access. Interviews with 21 drug injectors and 21 pharmacy staff. Overall there was good acceptance of the concept, although some misinformation about naloxone, some concerns about drug user and pharmacy staff interactions, and some concerns about cost.

Hempstead K, Yildirim EO.
Health Econ. 2013 Jun 6. doi: 10.1002/hec.2937. [Epub ahead of print]
Comment: Fascinating.

Knowlton A, Weir BW, Hazzard F, Olsen Y, McWilliams J, Fields J, Gaasch W.
Prehosp Emerg Care. 2013 Jul-Sep;17(3):317-29. doi: 10.3109/10903127.2013.792888.
Comments: Unable to access, so I’m unclear on details from this paper.

Wermeling DP.
Drug Deliv Transl Res. 2013 Feb 1;3(1):63-74.
Comments: Unable to access. A review of the rationale for nasal delivery of naloxone.

Rosen K, Gutierrez A, Haller D, Potter JS.
Clin J Pain. 2013 May 30. [Epub ahead of print]
Comments: The use of buprenorphine for chronic pain is an exciting idea whose time has come.

Sunday, 7 July 2013

New site NaloxoneInfo.org is chockablock with overdose prevention resources

Interested in learning more about opioid overdose and how to build prevention projects? The recently launched NaloxoneInfo.org site is worth a look. Made live during the International Harm Reduction Conference in June 2013, the site was developed by the Open Society Foundations in collaboration with Population Services International, Harm Reduction International, the Eurasian Harm Reduction Network, the Scottish Drugs Forum, Harm Reduction Coalition, and the Asian Network of People Who Use Drugs. 

The site is currently available in English and Russian and includes background information on overdose by region, a number of useful case studies, and tons of freely downloadable program, training, and advocacy materials that should help anyone starting a project.